The OS curve for the 12 patients in the first subgroup–FLT3-ITD negative AML with co-occurring high-risk mutations as defined by the IGP model (TET2, ASXL1 and/or PHF6)–was not significantly different from the OS curves for patients with unfavorable cytogenetics or patients with intermediate IGP risk (adjusted p = 0.111 and p = 0.919, respectively; Fig 2C). This evidence concerns the gene ASXL1 and acute myeloid leukemia.